Back to research

Research paper

Epileptogenesis and Epilepsy Treatment: Advances in Mechanistic Understanding, Therapeutic Approaches, and Future Perspectives

Review of epileptogenesis mechanisms in DEE-SWAS and implications for treatment sequencing. Cited twice in the 2026 Manus AI review (refs [7] and [42]). Covers thalamocortical circuit dysfunction, sleep-homeostasis disruption, and targeted treatment rationales.

Indexed context

Mazhit A, et al.

dee-swasepileptogenesisthalamocorticaltreatmentreview2026

Markdown path

content/research/papers/2026-mazhit-epileptogenesis-treatment-review.md

Findings

Review of epileptogenesis mechanisms in DEE-SWAS and implications for treatment sequencing. Cited twice in the 2026 Manus AI review (refs [7] and [42]). Covers thalamocortical circuit dysfunction, sleep-homeostasis disruption, and targeted treatment rationales.

Why it may matter for Levi

Mechanistic framing aligns with the existing corpus emphasis on thalamocortical circuit dysfunction and sleep-homeostasis disruption (Tononi-Cirelli SHY, Bolsterli slow-wave downscaling, Kramer/Chu spindle work). Reinforces existing differential weighting rather than adding new theory.

Paper text

Mazhit et al. (2026) — Epileptogenesis and epilepsy treatment mechanistic review

Source

  • PMC12897611. 2026.

Why in corpus

Recent mechanistic review linking neuroinflammation to epileptogenesis and highlighting anti-inflammatory therapeutic strategies relevant to DEE-SWAS.

Key findings

  • Reviews sleep-homeostasis disruption, neuroinflammation, and network-level dynamics as contributors to epileptogenesis.
  • Anti-inflammatory strategies — including IL-6 blockade (tocilizumab) and broader immunomodulation — have shown promise in refractory status epilepticus.
  • Points to chronic neuroinflammation in DEE-SWAS as a potential therapeutic target beyond standard corticosteroids.

Levi-relevant takeaways

  • Adds conceptual support for targeting Levi's Th1/Th17-weighted cytokine signature with immunomodulation beyond corticosteroids if steroid durability is limited.
  • Tocilizumab (IL-6 blockade) is used in refractory status epilepticus and in autoimmune encephalitis — off-label for DEE-SWAS but mechanistically grounded. Would be a specialist-coordinated decision.
  • Reinforces inclusion of IL-6 (serum + CSF) in every future cytokine panel for Levi.